Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.68 |
| ▸ | GLP1R | P43220 | 2/20 | 0.67 |
| ▸ | GCGR | P47871 | 1/20 | 0.67 |
| ▸ | GIPR | P48546 | 1/20 | 0.67 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.65 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.62 |
| ▸ | CCKBR | P32239 | 1/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.62 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416557 | 1.00 | TFPI (0.68) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL29496440 | 0.95 | VIPR1 (0.71) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL29701273 | 0.95 | TFPI (0.74) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL31182595 | 0.94 | GLP1R (0.68) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL29939512 | 0.92 | GLP1R (0.65) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL29405269 | 0.92 | VIPR1 (0.71) | TFPIGLP1RVIPR1VIPR2KISS1R | |
| SCHEMBL32681425 | 0.92 | VIPR1 (0.71) | TFPIGLP1RVIPR1VIPR2KISS1R | |
| SCHEMBL30038758 | 0.92 | VIPR1 (0.63) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL197505 | 0.92 | GLP1R (0.71) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL34139 | 0.92 | GLP1R (0.71) | TFPIGLP1RGCGRGIPRVIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035456-A1 | ANTI-ADRENOMEDULIN NON-NEUTRALIZING ANTIBODY, METHOD FOR PREPARING SAME, AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4559936-A1 | ANTI-ADRENOMEDULIN NON-NEUTRALIZING ANTIBODY, METHOD FOR PREPARING SAME, AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017331-A1 | ANTI-ADRENOMEDULIN NON-NEUTRALIZING ANTIBODY, METHOD FOR PREPARING SAME, AND USE THEREOF | 上海济煜医药科技有限公司 | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035456-A1 | ANTI-ADRENOMEDULIN NON-NEUTRALIZING ANTIBODY, METHOD FOR PREPARING SAME, AND USE THEREOF | ADM2, VIP, KDR | TFPI 2289/4885GLP1R 259/4885GCGR 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.